Trial Profile

Intermediate-size Patient Population Expanded Access Protocol for SPG302 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 26 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SPG 302 (Primary)
Indications Amyotrophic lateral sclerosis
Focus Expanded access; Therapeutic Use
Sponsors Spinogenix

Most Recent Events

28 Jul 2025 Status changed from planning to recruiting.
09 May 2025 New trial record
05 May 2025 Accoriding to Spinogenix media release, the company has received notification from the Food and Drug Administration (FDA) to begin its Expanded Access Program (EAP)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com